Tissue Regenix Group PLC Hardman & Co Research Report on: Tissue Regenix
August 03 2016 - 2:15AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
03 August 2016
Hardman Research: Major progress in orthopaedics
Major progress towards orthopaedics approvals: Tissue Regenix is
now in the commercialisation phase having validated its dCELL(R)
technology to produce 'like-for-like' tissue specific,
structure-preserving scaffolds for use in multiple clinical
settings. DermaPure has started well in the US for treating chronic
wounds and traction will increase now that it is widely reimbursed
by Medicare providers. But newsflow in the next 12 months is likely
to be dominated by the approval and launch of the orthopaedics
products for meniscal and tendon repairs. Despite short term
monthly cashburn of c.GBP1m, TRX is building long term value,
evidenced by 32p NPV driven by three core product areas.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/03-08-16-major-progress-towards-orthopaedics-approvals
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Dorothea Hill
Yard dmh@hardmanandco.com
London Dr Gregoire Pave
EC2R 7AS gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGGRVZLGVZM
(END) Dow Jones Newswires
August 03, 2016 02:15 ET (06:15 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024